To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Predictors and correlates… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes.

Journal article
Authors Magnus O Wijkman
Mary Dena
Sofia Dahlqvist
Sheyda Sofizadeh
Irl Hirsch
Jaakko Tuomilehto
Johan Mårtensson
Ole Torffvit
Henrik Imberg
Aso Saeed
Marcus Lind
Published in Journal of clinical hypertension (Greenwich, Conn.)
Volume 21
Issue 1
Pages 105-115
ISSN 1751-7176
Publication year 2019
Published at Institute of Medicine, Department of Molecular and Clinical Medicine
Pages 105-115
Language en
Subject categories Endocrinology and Diabetes


Liraglutide is associated with blood pressure reduction in patients with type 2 diabetes. However, it is not known whether this blood pressure reduction can be predicted prior to treatment initiation, and to what extent it correlates with weight loss and with improved glycemic control during follow-up. We analyzed data from a double-blind, placebo-controlled trial, in which 124 insulin-treated patients with type 2 diabetes were randomized to liraglutide or placebo. We evaluated various baseline variables as potential predictors of systolic blood pressure (SBP) reduction, and evaluated whether changes in SBP correlated with weight loss and with improved glycemic control. A greater reduction in SBP among liraglutide-treated patients was predicted by higher baseline values of SBP (P < 0.0001) and diastolic blood pressure (P = 0.012), and by lower baseline values of mean glucose measured by continuous glucose monitoring (CGM; P = 0.044), and serum fasting C-peptide (P = 0.015). The regression coefficients differed significantly between the liraglutide group and the placebo group only for diastolic blood pressure (P = 0.037) and mean CGM (P = 0.021). During the trial period, SBP reduction correlated directly with change in body weight and BMI, but not with change in HbA1c. We conclude that patients with lower mean CGM values at baseline responded to liraglutide with a larger reduction in SBP, and that improved HbA1c during follow-up was not associated with reductions of SBP. Our data suggest that some patients with type 2 diabetes may benefit from liraglutide in terms of weight and SBP reduction.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?